During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Can Recursion accelerate the time frame for drug discovery? Last year, Recursion announced that tech giant Nvidia invested $50 million into its operations. Together, the businesses are working on drug ...